TSHA — Taysha Gene Therapies Cashflow Statement
0.000.00%
Last trade - 00:00- $1.13bn
- $885.28m
- $8.33m
Annual cashflow statement for Taysha Gene Therapies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -60 | -175 | -166 | -112 | -89.3 |
| Depreciation | |||||
| Non-Cash Items | 29.4 | 28.3 | 56.6 | 54 | 18.1 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.111 | 28.7 | 19.8 | -16.8 | -11.3 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -30.7 | -117 | -88.4 | -73 | -81.2 |
| Capital Expenditures | -0.082 | -15.3 | -20.6 | -3.87 | -0.374 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -9 | -6.25 | -4.31 | -3.48 | 0.011 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -9.08 | -21.6 | -24.9 | -7.35 | -0.363 |
| Financing Cash Flow Items | — | -0.874 | 10.2 | -1.01 | -0.185 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 291 | 39.1 | 52.1 | 136 | 76.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 251 | -99.5 | -61.2 | 56 | -4.9 |